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Lower respiratory tract infections (LRTIs), including communi-
ty-acquired pneumonia (CAP) and tuberculosis (TB), are listed
among theWorld Health Organization’s (WHO’s) top 10 global
causes of death.1 TB is arguably one of the biggest killers of
mankind with almost a billion people succumbing to the
disease in the last two centuries. LRTI, synonymous with CAP,
remains themost deadly communicable disease, which caused
almost3milliondeathsglobally in2016.1 In2018 therewerean
estimated 10 million new TB cases and approximately 1.2
million deaths due to TB.2 Although both TB and CAP are
infections of the lower respiratory tract, they are often thought
of as separate entities as TB is classically a more indolent
disease presenting over weeks to months and, often, is not
associatedwithacute respiratorycompromise. Bycontrast, CAP
is generally associated with a short history of several days, is
rapidly progressive, and is more often associated with respira-
tory compromise. However, although there is good evidence to
the contrary, it is widely believed thatMycobacterium tubercu-
losis is not an important cause of CAP,which is an acute disease.
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Abstract According to World Health Organization estimates, tuberculosis (TB) and lower
respiratory tract infections (LRTIs) are both among the top 10 global causes of death.
TB and community-acquired pneumonia (CAP), if mortality estimates are combined,
would rank as the third most common cause of death globally. It is estimated that each
year there are approximately 10 million new cases of TB that are associated with
approximately 1.2 million deaths, and almost 450 million new episodes of LRTI
(synonymous with CAP) with approximately 4 million associated deaths. Globally,
Streptococcus pneumoniae remains the most common cause of CAP. However, although
well documented, it is not widely appreciated that in several parts of the world,
including sub-Saharan Africa, Asia, and South America,Mycobacterium tuberculosis is an
important cause of CAP, if not the most common organism isolated in such settings.
Thus, CAP due toM. tuberculosis is not uncommon in some parts of the world with up to
a third of cases being attributable to M. tuberculosis. Consequently, TB remains an
important clinical entity in the intensive care unit in these settings. Despite its
frequency and importance, there are very limited data about TB CAP. In this review
we discussed the epidemiology, immunopathogenesis, clinical presentation, diagno-
sis, management, prognosis, and prevention of TB CAP. The utility of newer diagnostic
approaches is highlighted.
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human immunodeficiency virus (HIV)-endemic settings,
TB-associated CAP (TB CAP) is not uncommon.3 Indeed, in
several parts of theworld,M. tuberculosis is the most common
pathogen isolated in those with presumed CAP. Despite the
importance of this entity, to our knowledge, therehavebeenno
detailed reviews onTB CAP. This article provides a comprehen-
siveoverviewofTBCAPanddiscusses theepidemiology, clinical
presentation, immunopathogenesis, diagnosis, and clinical
management of TB CAP. Other aspects such as posttuberculous
lung disease and preventing TB CAP are also addressed.
Epidemiology
Although the incidence of TB has been slowly declining over
several years, it is far from eradicated, and TB remains among
the top 10 killers globally.1,4 Although TB continues to occur
in almost every part of the world, the eight highest burden
countries (India, China, Indonesia, the Philippines, Pakistan,
Nigeria, Bangladesh, and South Africa) represent almost two-
thirds of the total disease burden. The 22 high-burden TB
countries include Angola, Bangladesh, Brazil, China, DPR
Korea, DR Congo, Ethiopia, India, Indonesia, Kenya, Mozam-
bique, Myanmar, Nigeria, Pakistan, Philippines, Russian
Federation, South Africa, Thailand, Tanzania, Viet Nam,
Cambodia, and the Central African Republic.2 There are
also many intermediate-burden countries, which include
those in South East Asia and South America, where TB is
still rife. There are several cross-cutting themes that modu-
late the presentation, diagnosis, and management of TB
and TB CAP, including HIV co-infection, drug-resistant TB
(DR-TB), and TB in children. Indeed, HIV-infected persons are
exquisitely susceptible toTB with an over 100-fold increased
risk of TB infection compared with HIV-uninfected persons.
Globally, there are almost 500,000 new cases of multidrug-
resistant (MDR)-TB or extensively drug-resistant (XDR)-TB
annually and approximately 25% of allM. tuberculosis isolates
are resistant to at least one major anti-TB drug. Approxi-
mately 11% of the TB burden is in children and TB CAP
remains an important entity in this vulnerable subpopula-
tion. Clinical presentation in HIV-infected patients5 is
atypical and lack of cavitary disease, and lower lung zone
infiltrates, consolidation, pleural effusion, and lymphade-
nopathy are more common. TB control in several parts of
the world is being subverted by the resurgence of MDR-TB;
resistance to rifampicin and isoniazid, the two frontline
antituberculous drugs. EDR-TB (additional resistance to
fluoroquinolones and aminoglycosides) has also increased
globally. Despite the use of newer second-line drugs such as
bedaquiline and linezolid, approximately 25% of patients
with MDR-TB and approximately 35% with XDR-TB6,7 still
have poor outcomes. In countries like South Africa, the total
burden of DR-TB is approximately 5% and therefore suscep-
tibility testing is routinely performed in all isolates. About
15% of the burden of TB is in childrenwho often present with
atypical radiological features and confirming the disease
microbiologically in this subgroup is challenging.8,9 These
three cross-cutting themes have relevance to the epidemiol-
ogy, diagnosis, and management of TB CAP.
How Common Is TB CAP?
►Table 1 outlines the frequency of TB CAP in those presenting
with acute LRTI. Collectively, the frequency of TB CAP varied
from 1% in Beijing, China10 to almost 61% in Cote d’Ivoire.11
Overall, there seemed to be a higher prevalence of TB CAP in
those presenting with acute LRTI in HIV-endemic countries.
For example, in a large study conducted in Pietermaritzburg in
the KwaZulu-Natal Province of South Africa (the study HIV
prevalence rate was 69%), the prevalence of TB CAP in those
presenting with acute LRTI was approximately 14%.12Notably,
M. tuberculosiswas the most common pathogen associated in
those with CAP with Streptococcus pneumoniae being
the second most frequent. In a report on CAP from a tertiary
center in Durban, South Africa (study HIV prevalence rate of
81% and involving 430 participants), M. tuberculosis was the
causative pathogen in 40% of HIV-infected and 35% of HIV-
uninfected persons.13 Again, M. tuberculosis was the most
frequent pathogen isolated with S. pneumoniae being
the second most frequent pathogen isolated. A study in
Botswana recruiting 1,305 patients found the prevalence of
TBCAP tobe5.2% (87%of thosewith CAPwereHIV-infected).14
Similarly, a study inKenya found theprevalenceofTBCAP tobe
9%, and 52% of those with CAP were HIV-infected.15
In non-HIV-endemic areas there is also an appreciable
prevalence of CAP in those presenting with acute LRTI. For
example, a study from Hong Kong that enrolled 1,193
participants whowere HIV-uninfected, found the prevalence
of TB CAP in acute LRTI to be 8.1%.16 A study from the rural
Philippines that recruited 535 patients found the prevalence
of TB CAP to be 9.8%,17 and prospective multicentric studies
from Cambodia and Vietnam (but in HIV-infected persons)
found a TB CAP prevalence of 20 and 19%, respectively.18 By
contrast, in a low HIV prevalence setting like Iran, 17.5% of
120 participants who presented with acute LRTI were found
to have TB CAP.19
A systematic review involving children, mainly from TB-
endemic countries, found that the TB CAP prevalence rate
was 7.5% among 7,045 participants.20 A systematic review
interrogating the bacterial etiology of CAP in Asian adults
that included 10,423 patients from 48 studies found that
gram-negative bacilli and M. tuberculosis were more impor-
tant pathogens with S. pneumoniae being of less relative
importance21; by contrast, in north east Thailand Burkhol-
deria pseudomallei was a major pathogen.22 The authors
highlighted that these epidemiological findings have major
implications for the local selection of diagnostic and empiri-
cal treatment strategies of CAP. They further concluded that
narrow-spectrum antibiotics targeting S. pneumoniae may
be inappropriate in many Asian settings.
Pathogenesis
The pathogenesis of TB CAP is poorly understood but probably
represents an endpoint of different immunopathological tra-
jectories including (1) acute progressive TB pneumonia, (2)
superadded infection with bacteria or viruses in those with
subclinical TB, and (3) initial bacterial or viral pneumonia
with increased susceptibility to and superimposed infection
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with M. tuberculosis. In TB-endemic countries, approximately
1 to 2 percent of the population in informal settlements and
shanty towns may have active TB.23–25 Consequently, in some
cases, acute LRTI may precipitate clinical presentation with
recovery of M. tuberculosis during investigation but failure to
culture or identify the relevant viral or bacterial pathogen.
Recovery of more than one pathogen in those with TB CAP
supports this hypothesis. Indeed, in various TB CAP-associated
studies, co-infectionwith different organisms including influ-
enza, S. pneumoniae, and Acinetobacter/Enterobacter was not-
ed in 1, 14.3, and 9% of patients, respectively.12,13,26 It remains
unclear if the recoveredorganismswere colonizing bystanders
or represented disease-causing entities, thus contributing to
hypoxia and the clinical features at presentation. It is likely
that both possibilities are tenable. The interaction between
bacteria such as pneumococcus, Haemophilus influenzae and
viruses like influenza, and increased susceptibility to TB with
accelerated presentation remain unstudied. However, in a
phase 3 studywith almost 40,000 participants, pneumococcal
vaccination was associated with a 40% reduction in culture-
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40 in HIV þve
35 in HIV ve
Consecutive patients over a 17-month period.
HIV and TB endemic area
13
Kenyaa,b,c 281 9 52% of CAP HIV infected 15
Cote d’Ivoire 200 61 Cross-sectional study of HIV-infected patients with CAP 11
Central African
Republica,b
101 60 Prospective multicenter study in HIV-infected




81 6 Prospective CAP study over 5 months 124
Senegal 70 24 Prospective multicenter study in HIV-infected
persons with smear negative sputum
18
TB endemic areas 7,045 7.5 Systematic review in children 20
Hong Kong 1,193 8.1 Prospective study of non-HIV-infected CAP 16
Hong Kong 90 12.2 Prospective study of non-HIV-infected CAP 26
Pan Asia 955 3.3 Prospective surveillance of CAP in 8 countries 125
Philippinesa,c 535 9.8 Prospective CAP study 17
South Korea 528 7 High TB prevalent suburban area 35
Japan 349 1.7 Prospective CAP study 126
Japan 326 1.5 Prospective CAP study 127
Malaysia 346 4.9 Prospective CAP study; HIV testing not performed 3
Malaysia 108 10.2 Prospective CAP study 128
Malaysia 98 15.3 Prospective CAP study; HIV-infected persons excluded 129
Indiaa,b,c 233 5.1 Prospective study of CAP 130
China,a,b,c Beijing 197 1 Consecutive outpatient recruitment of CAP 10
Cambodia 193 20 Prospective multicenter study in HIV-infected
persons with smear negative sputum
18
Taiwan 168 1.2 Prospective CAP study 131
Taiwan 100 2 Prospective CAP study 132
Iran 120 17.5 Low HIV prevalence setting 19
Thailanda,c 119 2 Hospitalized CAP including HIV-infected persons 22
Vietnama,c 98 19 Prospective multicenter study in HIV-infected
persons with smear negative sputum
18
Singapore 96 21 Prospective CAP study 133
Abbreviations: HIV, human immunodeficiency virus; CAP, community-acquired pneumonia; MDR, multidrug resistant; TB, tuberculosis.
aHigh TB burden country by absolute number.
bHigh TB-HIV burden country by absolute number.
cHigh MDR-TB burden country by absolute number.
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confirmed TB among hospitalized vaccinated patients com-
pared with those who remained unvaccinated over a 5.3-year
follow-up period.27 It is possible that the pneumococcal
vaccination prevented bacterial superinfection in TB cases or
alternatively may have acted through reducing enhanced
susceptibility (it is likely a combination of these possibilities).
Alternatively, M. tuberculosis may rapidly progress and
present as lobar consolidation and pneumonia. This type of
presentation, sometimes referred to as progressive primary
disease, is more commonly seen in children but may also
be seen in adults.28 Reasons for rapid progression of TB to
lobar consolidation and pneumonia-like presentation with
lack of granuloma containment are poorly understood. How-
ever, it is likely related to genetic and acquired immune
dysfunction that fails to contain M. tuberculosis and retard
disease progression. Clinical experience and published data
suggest that autophagy, CD4 T-cells, CD8 T-cells, tumor
necrosis factor (TNF)-α, regulatory T-cells, and other myco-
bactericidal mechanisms (including granzyme, cathelicidin,
and the vitamin D pathways) are likely to be important in
protecting against M. tuberculosis; however, a clear-cut
protective biosignature has, hitherto, not been clarified.29,30
Thus, the immunopathogenesis of TB is poorly understood
and there are no well-accepted correlates of protective
immunity. It is likely that immune paresis is the likely
mechanism as TB CAP is more common in HIV-infected
persons (and in those with advanced immunosuppression),
and HIV co-infection increases susceptibility to TB and
accelerates progression through subversion of macrophage
and CD4 T-cell responses.31
Other factors that could influence presentation and the
evolution to TB CAP, compared with the more indolent
presentation of apical cavitary disease, may include strain
type, the force of infection or intensity of exposure, and host–
pathogen interaction, i.e., inflammatory response at the level
of host-adaptive immunity.32
Clinical Presentation
TB CAP may be difficult to differentiate clinically from non-TB
pneumonia (non-TBCAP)onclinical andradiologicalgrounds.26
This results in delay in the diagnosis of TB thus increasing not
only morbidity and mortality but also the nosocomial and
nonnosocomial transmission of TB.33 However, can clinical
and radiological features help distinguish TB CAP from non-TB
CAP? In a multivariate analysis of 6,976 patients hospitalized
with CAP (TB CAP and non-TB CAP), Cavallazzi and colleagues
derivedfive independent predictors of TB CAP, i.e., night sweats,
hemoptysis, weight loss, M. tuberculosis exposure, and upper
lobe infiltrate.34 Similarly, Chon et al, in a study with TB CAP
prevalence of 7%, identified symptoms >7 days, upper lobe
involvement, night sweats, cavitary/nodular infiltrates, and a
serum albumin<3.5 g/dL as independent predictors of TB. Two
ormorefactorshadasensitivityandspecificityof81.1and75.8%
respectively with a positive predictive value of 24.4% (if at least
two of these factors were present) and a negative predictive
value of 97.9% (if none of these factors were present).35 In
addition, longer duration of symptoms, leucopenia, and lym-
phopenia were also predictive of TB CAP.3,36 A pleural effusion
and upper lobe involvement were the radiographic features
morecommonlyseenwithTBCAP.26Acourseofantibioticswith
assessment of clinical and radiologic response was found to be
better than derived scores in predicting TB CAP. In one study, a
failure to respond to a course of amoxicillin had a positive
predictive value of 91% and a negative predictive value of 94%.37
Tuberculosis in the Critically Ill and the ICU
A diagnosis of TB in the intensive care unit (ICU) in TB-
endemic countries is not uncommon. However, theremay be
different categories of TB patients admitted to the ICU. A
subset may be admitted to the ICU because of TB CAP.
Alternatively, patients may have had prior active TB and
are then admitted to the ICU because of sepsis or other
complications, or TB may have been incidentally discovered
in patients admitted to the ICU for unrelated reasons, e.g.,
trauma (subclinical TB), and rarely due to disseminated TB-
associated acute respiratory distress syndrome.38 Thus, the
most common indication for TB-related ICU admission is
acute respiratory failure or multiorgan failure; however,
often, these complications may not be directly related to
TB.38–42 Other potential indications for ICU admission are
massive hemoptysis, cardiogenic shock, and neurological
deterioration in patients with tuberculous meningi-
tis.38,43–45 Thus, there are no data specifically on TB CAP
and outcomes in the ICU; this is an area that warrants further
study. Nevertheless, in our experience, the mortality rate
remains high in patients with TB CAP requiring mechanical
ventilation and is estimated to be twice as high as non-TB
CAP requiring mechanical ventilation.45 A mortality rate of
69% was noted in a Canadian study of TB patients requiring
mechanical ventilation.46 Similarly, a high mortality rate of
65.9% was recorded by Lee and colleagues at a tertiary
hospital in Taiwan in patients with active TB requiring
mechanical ventilation.45A retrospective review in Germany
recorded a mortality rate of 22.4%, which is similar to that of
non-TB CAP requiring mechanical ventilation.44 More re-
cently, in a prospective study in a TB-endemic setting,
Calligaro and colleagues reported ICU mortality of 27% and
in-hospital mortality of 31% at a tertiary hospital in Cape
Town, South Africa.38 In this study, patients with known
prior active TB requiring ICU admission were analyzed
separately. Importantly, they observed that mortality in
patients diagnosed with TB in ICU was no different to that
of other critically ill patients without TB. However, in the
same city but in a different ICU, Balkema et al prospectively
enrolled active and subclinical TB patients and reported an
ICU and in-hospital mortality of 44.2 and 59%, respectively.43
Mortality rates of 22 to 70% have been observed in TB–HIV
co-infected patients admitted to the ICU.41,42,47
In summary, risk factors associated with increased mor-
tality in ICU (and not specifically due to TB CAP
alone) include older age, mechanical ventilation, multi-
organ failure, APACHE II score of >20, hemodynamic insta-
bility requiring vasopressors, nosocomial pneumonia, and
delayed initiation of antituberculous treatment.38,43–45,47 In
Seminars in Respiratory and Critical Care Medicine Vol. 41 No. 4/2020



















































addition to the above risk factors, advanced immunosup-
pression, hypoalbuminemia, and lymphopenia are predic-
tors of increased mortality in TB–HIV co-infected patients in
the ICU.41,42,47
Diagnosis of TB CAP
The Challenge of Biological Sample Acquisition
Most of the diagnostic tests for TB rely on expectoration of a
good sputum sample. Some patients may not be able to
expectorate sputum. Indeed, 64% of HIV-uninfected persons
withnon-TBCAPare sputumscarce.48 InHIV-infectedpatients
with pulmonary TB in general (not specific to TB CAP), up to a
third of patients are unable to produce sputum for diagnostic
testing.49 In addition, in this subgroup thebacillary load in the
sputum is low and thus, a significant proportion are sputum
smear negative.50–52 We have demonstrated that sputum
induction and bronchoalveolar lavage aid sputum acquisition
in smear-negative and sputum-scarce patients with good
results and should be used when appropriate.53–55 Tracheal
aspirates from patients on mechanical ventilation have also
been shown to yield good results.38 In summary, when test
results are negative, this may be due to sampling error, i.e.,
poor quality sputum, and thus teaching patients how to
properly expectorate sputum is important.
Nonspecific Discriminatory Biomarkers
Distinguishing TB CAP from Non-TB CAP
As outlined, differentiating TB CAP from non-TB CAP
on clinical and radiologic grounds is often challenging.
However, procalcitonin (PCT) and C-reactive protein (CRP),
which are markers of inflammatory response to infection,
differ significantly between TB CAP and non-TB CAP. PCT and
CRP are generally significantly higher (both in HIV-infected
and uninfected persons) in bacterial/non-TB CAP than in TB
CAPwith sensitivity ranging from 43 to 87% for PCT and 78 to
83% for CRP, while specificity for PCT ranged from 78 to 88%
and that for CRP from 75 to 83%. Positive and negative
predictive values for PCT ranged from 65 to 67% and 74 to
91%, respectively, while that for CRP from 64 to 82% and 65 to
89%, respectively.56–59 These values although broadly dis-
criminating fail to achieve thresholds that make them useful
for clinical practice (would rule in or exclude only roughly
two-thirds of individuals). Yoon and colleagues identified a
neutrophil-to-lymphocyte ratio <7.0 as the optimal cut-off
value for distinguishing patients with TB CAP from patients
with bacterial non-TB CAP, yielding 91.1% sensitivity, 81.9%
specificity, 85.7% positive predictive value, and 88.5% nega-
tive predictive value.60 The triggering receptor expressed on
myeloid cells (TREM)61 is a recently describedmember of the
immunoglobulin superfamily expressed on blood phago-
cytes and alveolar macrophages. TREM-1 is selectively
expressed in the lungs of patients with bacterial non-TB
CAP and not inTB CAP.61 Further studies are needed to clarify
its utility in distinguishing TB CAP from other causes of CAP.
Confirmatory Microbiological Tests forM. tuberculosis
(►Fig. 1)
Confirmation of a TB diagnosis is challenging. Globally, only
just over 50% of TB is microbiologically confirmed.62 In most
Fig. 1 Currently available sputum and urine-based tools for the microbiological diagnosis of drug-sensitive and drug-resistant tuberculosis.
The WHO-approved Cepheid GeneXpert MTB/RIF and Hain Lifescience line probe assay have been depicted but other nucleic acid amplification
tests (NAAT) such as Amplified Mycobacterium Tuberculosis Direct (MTD) test by Gen-Probe Inc., and Amplicor Mycobacterium Tuberculosis Test
by Roche Molecular Systems are also FDA-approved and commercially available. DST, drug susceptibility testing; FDA, Food and Drug
Administration; FQ: fluoroquinolones; INH, isoniazid; RIF, rifampicin; SLID, second-line injectable drugs (e.g., kanamycin and amikacin).
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high TB-burden settings, despite the advent of molecular
diagnostics, smear microscopy remains the standard of care
though the sensitivity is only approximately 50%.63 The
sensitivity of same-day smear microscopy can be improved
by approximately 10% after sample centrifugation and use of
fluorescence microscopy.64 The quasi-gold standard confir-
matory test is automated liquid culture, which has a limit of
detection of approximately 10 organisms per mL and is more
sensitive. However, it is more costly and more prone to
contamination than solid media.65,66
Nucleic acid amplification tests are now available as con-
firmatory tests and theWHO has endorsed the use of the Hain
MTBDRplus and MTBDRsl assays and Gene Xpert MTB/RIF,
now superseded by Xpert Ultra, for the diagnosis of TB.67 In a
multicentric study, Xpert Ultra had a sensitivity of 97.8% in
smear positive, 78.9% in smear-negative pulmonary TB, with
high specificity and a level of detection in sputum of 15.6
organisms/mL.68 By contrast, the sensitivity of Xpert is subop-
timal in TB serositis (pericarditis, pleural and peritoneal
TB).69,70 Although Xpert assays are cost-effective and enable
rapid detection of rifampicin-resistant TB, they are unable to
detect isoniazid monoresistant TB, might remain positive for
several years after completion of treatment (therefore often
positive in thosewith previous TB),53,71 and cannot be used to
monitor treatment.72,73 Furthermore, although Xpert enables
amore rapiddiagnosis, it failed to showaclear-cut reduction in
morbidity,mortality, and impact on theburden of TB.74–76 The
latter is not surprising given thatmost TB transmission (>95%)
has occurred prior to patients presenting to health care
facilities for treatment.
Alternative confirmatory susceptibility testing is advis-
able in regions where MDR TB prevalence is less than 10%
because of the modest positive predictive value of Xpert or
rifampicin resistance.67 Genotypic resistance testing beyond
rifampicin, including second-line drugs, may be undertaken
using multiplex molecular assays, e.g., the Hain MTBDRplus
and MTBDRsl using TB isolates or smear-positive sputum.77
Targeted or next-generation sequencing is being investigated
but the technology is not yet ripe for use in clinical practice
and its impact on treatment outcome still needs to be
established.78 However, as technology improves, next-gen-
eration sequencing has great potential for rapid diagnosis of
drug-resistant TB in diverse clinical settings once several
hurdles are overcome.79
The urine lipoarabinomannan (LAM) point-of-care lateral
flow assay is a useful low-cost test in patients with advanced
HIV, especially in those with CD4 count less than 100 cells/mL
and particularly in patientswho are sputum scarce. Even in this
group, although sensitivity is only approximately 30 to 40%, its
use in HIV-endemic settings has demonstrated a mortality
benefit.49 LAM sensitivity increases with decreasing CD4
count.49,80
In summary, in TB and HIV high- and intermediate-burden
settingswhere TBCAP comprises a significant proportion of all
patients with CAP, patients should be routinely tested for TB.
Molecular,microscopic, antigen-based, andculture-basedtest-
ing should be used depending on the clinical and situational
context. This has a bearing onmorbidity and mortality as well
as nosocomial transmission of TB to health care workers
and patients without TB.81,82 Finally, to confirm the diagnosis
and direct therapy, appropriate ancillary testing for other
causes of CAP should be undertaken including tests for Pneu-
mocystis jirovecii (PJP), viruses, fungi (including PJP), and
bacteria (including blood and sputum culture, and serological
and antigen-based testing for Legionella and atypical bacteria).
Clinical Management of TB CAP
Treatment of TB CAP is generally no different from treatment
of other forms of TB.
Drug-Sensitive TB
The current 6-month regimen for drug-sensitive TB was
derived in the 1970s and is still highly effective. Given the
long duration of therapy treatment, default rates can be
substantial.83 African patients on TB treatment had delayed
lower sputum conversion rates,84 likely as a result of lower
levels of rifampicin in Black Africans85 related to drug metab-
olism by liver enzymes, e.g., there is a high frequency of a
polymorphism in SLCO1B1 gene.86 To improve adherence,
directly observed therapy (DOT) was widely implemented.
However, ameta-analysishasshownthatDOTisnobetter than
self-administered therapy in preventingmicrobiologic failure,
relapse, or adverse drug reactions.87Drug-induced liver injury
is the most serious side effect of treatment.88
Adjunctive Corticosteroids for TB CAP
Adjunctive steroid use remains controversial inTB CAP as it is
in non-TB CAP.89,90 There is no proven indication for steroids
in TB CAP unless the patient has concomitant tuberculous
meningitis where steroids reduce death and neurological
deficit, or tuberculous pericarditis where a mortality benefit
was noted.91,92 However, a large study done in South Africa
evaluating efficacy of steroids in tuberculous pericarditis did
not showamortality benefit, though therewas a reduction in
the development of constrictive pericarditis.93 Adjunctive
steroids are also indicated in patients with severe TB CAP
requiring vasopressors and/or with adrenal insufficiency.94
The downside of steroid use includes gastrointestinal bleed-
ing, hyperglycemia, exacerbation of immune paralysis, and
superinfection,95 and increased incidence of cancer in HIV-
infected patients who are not on antiretroviral therapy.93
Thus, use of steroids in TB CAP must be individualized and is
clinical-context-dependent.
Therapeutic Drug Monitoring
It has nowbeen established that the pharmacokinetics of anti-
TB drugs is influenced by several factors including patient
demographic profile including age, sex and ethnicity, gastro-
intestinal motility, drug formulation, and co-administration
with other drugs leading to drug–drug interactions.96–100 The
recommended rifampicin dose of 10mg/kg, derived in the
1970s, was based mainly on perceived high cost and toxicity
considerations. Several studies have consistently shown that
lower than expected maximal drug concentrations was
associated with a poor clinical outcome.96,100–102 More
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recently, clinical studies of high-dose rifampicin, up to 35 -
mg/kg, demonstrated that it was associated with improved
pharmacokinetics, and higher early mycobactericidal activity.
Thus, rifampicin-based therapeutic drugmonitoring (TDM)100
is likely beneficial in certain patient subgroups such as those
who have poor prognostic features (and are thus slow to
respond to treatment), including HIV-infected persons, those
at risk of drug–drug interactions, in those with likely altered
drug pharmacokinetics, and in those with DR-TB.100 Con-
trolled trials on the impact of rifampicin-based TDM are
eagerly awaited.
Little is known about the pharmacokinetics of anti-TB
drugs in the ICU since it is modulated by several factors,
including enteral nutrition, gastroparesis, intestinal paraly-
sis, ulcer prophylaxis, and liver and renal dysfunction.103
Indeed, preliminary findings by Koegelenberg and col-
leagues showed that crushed fixed combination tablets
given via a nasogastric tube to TB patients in ICU was
associated with subtherapeutic levels of rifampicin espe-
cially in patients with higher APACHE II scores.104 This could
be circumvented by giving anti-TB drugs intravenously.
However, only rifampicin and isoniazid are available as
intravenous injections.104 Given the above-mentioned con-
siderations, we recommend the use of rifampicin-based
TDM in appropriate patients including those with TB CAP
and in the ICU.
Treatment in TB–HIV Co-infected Patients
Recurrence of TB, generally from reinfection rather than
reactivation, is high in TB-HIV co-infected patients.105 Ri-
fampicin, which is a hepatic inducer of drug-metabolizing
enzymes and transporters, may lower concentration levels
necessitating increased doses of antiretroviral drugs or
switching to rifabutin, a weaker hepatic inducer.1 Immune
reconstitution inflammatory syndrome (IRIS)22 is an immu-
nopathological response usually seen at least 2 weeks after
initiation of antiretroviral therapy that may unmask TB or
paradoxically worsen TB manifestations. The risk of TB-IRIS
increases with falling CD4 count and is associated with a low
mortality.106 Oral prednisone reduced the need for hospital-
ization and therapeutic procedures, and hastened improve-
ment of symptoms in patients with TB-IRIS.107 In addition,
prednisone lowered the incidence of TB-IRIS.108 The same
considerations are likely to apply to TB CAP.
Management of TB CAP that Is Resistant to Frontline
TB Drugs
Two new drugs, bedaquiline and delamanid, have been
registered for use in DR-TB. Several other drugs including
later generation of fluoroquinolones, linezolid, and clofazi-
mine have been repurposed for the treatment of DR-TB. The
WHO has now newly grouped second-line drugs into Group
A (bedaquiline, fluoroquinolone, and linezolid), B (clofazi-
mine, cycloserine/terizidone), and C that include all the
remaining agents based on their impact on mortality and
treatment-related outcomes. Till recently, treatment success
rates forDR-TB havebeen only approximately 50%,109 and the
regimens have been toxic, poorly tolerated, and prolonged.
When treating rifampicin-resistant TB the WHO advises
that all three Group A agents and at least one Group B agent
should be included to ensure that at least four effective drugs
are used (ideally, we recommend that at least five likely
effective drugs should be used). A total treatment duration of
18 to 20months is suggested for most patients depending on
time to culture conversion, though in some settings like
South Africa shorter regimens are routinely being used.
Sputum culture and microscopy can be used to monitor
treatment response. The emergence of programmatically
incurable TB and discharge back into the community of
such patients has raised legal, ethical, and logistical dilem-
mas in high-burden settings as these patients remain
infectious.110,111
Prognosis and Outcome of TB CAP
In non-TB CAP, mortality varies between<1% and nearly 50%
depending on disease severity, initiation of timely appropri-
ate treatment, and other factors.18,112 By contrast, mortality
rates in TB CAP are reported to be between 7 and 70%
depending on severity and prognostic factors.18,43,47,113 In
a study conducted at a tertiary center in Durban, South
Africa, the overall mortality for CAP was 17% (15.7 and
26.7% in HIV-infected and uninfected groups, respectively).
In those with TB CAP, mortality in the HIV-infected and
uninfected groups was 26 and 11%, respectively. In the same
study in those with pneumococcal pneumonia, mortality in
the HIV-infected and uninfected groups was 18 and 22%,
respectively.13
Post-TB CAP Complications and Post-TB Lung
Disease
Pulmonary TB causes substantial chronic morbidity due to
lung remodelling32 resulting in chronic pulmonary obstruc-
tive disease,114 posttuberculous bronchiectasis, Aspergillus-
associated lung disease, and lung destruction.32 Those with
TB CAP are at risk of the same sequelae though little is known
about the nature of post-TB lung disease (PTBLD) in TB CAP
versus more indolent forms of TB. PTBLD causes progressive
disability and may be complicated by respiratory failure
and/or massive hemoptysis requiring either surgery or bron-
chial artery embolization. The pathogenesis of PTBLD is
poorly understood but may result from dysfunctional extra-
cellular matrix deposition and clearance.32 Aspergillomas in
the residual cavities may cause massive hemoptysis or
chronic pulmonary Aspergillus-associated disease.115
Prevention of TB CAP
There is currently no proven population-wide effective vaccine
for TB though a recent phase III trial showed promising
results.116 Bacille Calmette-Guerin (BCG), which is still admin-
istered at birth inmost TB-endemiccountries, provides approx-
imately 30% protection against TB in adults117 and protects
against disseminated form of TB, like TB-meningitis in chil-
dren.118 There is circumstantial evidence that vaccination
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against S. pneumoniae and influenza may afford some protec-
tion against M. tuberculosis and conversely that BCG may
provide protection against LRTI through the mechanism-
trained innate immunity.119 Identification and treatment of
latent TB infection (LTBI) is an important preventative strategy
that is used in certain high-risk groups in low-burden set-
tings120 and inHIV-infected persons and childrenunder 5 years
in resource-poor settings.121However, it is nowrecognized that
TB will never be eradicated without treating LTBI, which can
later spawn cases of active TB driving ongoing community-
based transmission. Hence, recentWHOguidelines have for the
first time conditionally approved identification and treatment
of LTBI in HIV-uninfected close contacts of index cases in TB-
endemic settings.122 In sub-Saharan Africa and other appropri-
ate settings, universal testing for HIV (or in certain high-risk
groups)with provision of antiretroviral therapy is an important
preventative measure given that HIV is a potent risk factor for
TB. Epidemiologically, at a population-based level, cigarette
smoking and biomass fuel exposure are even bigger drivers of
TB than HIV.1 Thus, smoking cessation and public health
interventions to minimize exposure to biomass fuels are an
important preventative strategy. Similarly, awareness cam-
paigns and public health strategies educating people about
TB, TB CAP, and non-TB CAP, including awareness about the
symptomsandrisk factors forTB, are important. It is remarkable
that two out of every five TB cases globally remain undetected!
62 Thus, community-based active case finding is a critical
preventative strategy to reduce the burden of TB in general.
Passive case finding (where patients self-seek medical care) is
currently the dominant public health strategy employed glob-
ally. However, with this approach more than 95% of transmis-
sion has already occurred prior to treatment initiation. Newer
portable molecular tools that can be used at point of care23
including development of new screening tools123 promises to
revolutionize community-based active case finding for TB.
Conclusion
TB CAP is more common than appreciated and is an impor-
tant cause of acute LRTI in Africa, Asia, and South America. TB
should be considered as part of the differential diagnosis and
should be specifically excluded in patients with CAP in these
settings. In low TB-burden settings, TB CAP should be
considered in high-risk groups including immigrants, HIV-
infected persons, and those with immunosuppressive con-
ditions including chronic organ dysfunction. Our ability to
rapidly diagnose TB has markedly improved and in countries
like South Africa, rapid molecular assays are frontline tools
that are available in almost every primary level clinic. Drug-
sensitive TB treatment is generally associated with good
outcomes and there is considerable work being undertaken
to find shorter and more effective treatment regimens.
Although there is no effective vaccine, treatment of LTBI in
appropriate settings and implementation of basic preventa-
tive measures such as BCG vaccination, HIV testing and
treatment, smoking cessation, and reduction in exposure
to biomass fuels are important preventative strategies.
However, until there is greater alleviation of poverty and
overcrowding, improved research funding, and improved
political will, TB, non-TB CAP, and TB CAP will continue to
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